Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI), Dexcom (DXCM) and Regeneron (REGN).
Aerie Pharma (AERI)
Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma today and set a price target of $77. The company’s shares closed yesterday at $38.70, close to its 52-week low of $32.18.
Yang observed:
“We are including weekly IQVIA Scripts for Rhopressa below. For the week ended 02/15/2019, Rhopressa TRx increased +2.0% to 5,495 from 5,388 the prior week; and Rhopressa NRx decreased -1.1% to 2,378 from 2,404 the prior week.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 15.6% and a 47.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $78.25, a 102.2% upside from current levels. In a report issued on February 12, Canaccord Genuity also reiterated a Buy rating on the stock with a $86 price target.
See today’s analyst top recommended stocks >>
Dexcom (DXCM)
Oppenheimer analyst Steven Lichtman maintained a Buy rating on Dexcom today and set a price target of $167. The company’s shares closed yesterday at $146.25, close to its 52-week high of $155.85.
Lichtman wrote:
“DXCM’s 4Q18 sales of $338M (+53%) significantly beat our/Street’s original $281M/ $285 (it pre-announced sales “above $331M” in early January). Outperformance versus our estimate came all in the U.S. (+50% y/y) on the ongoing G6 launch. International grew 72% with broad-based geographic strength. Gross margin topped expectations, and operating expense leverage was a particular highlight. EPS in 4Q18 was well ahead at $0.54 vs our original $0.16E on the higher sales and lower opex. Sales guidance for 2019 was reiterated at $1.175-1.225B; implied growth of 15-20% looks conservative based on trends coming out of ’18. G7 (Verily) remains on track for late ’20/early ’21. In the interim, DXCM anticipates continued introductions of product enhancements (including longer wear), further international expansion, pump/pen partnership launches and channel expansion.”
According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -4.2% and a 50.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Currently, the analyst consensus on Dexcom is a Moderate Buy with an average price target of $148.33, which is a 1.4% upside from current levels. In a report issued on February 8, Raymond James also maintained a Buy rating on the stock with a $160 price target.
Regeneron (REGN)
Regeneron received a Hold rating and a $425 price target from Guggenheim analyst Adnan Butt today. The company’s shares closed yesterday at $418.62, close to its 52-week high of $431.32.
Butt has an average return of 5.5% when recommending Regeneron.
According to TipRanks.com, Butt is ranked #3359 out of 5194 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $431.90 average price target, representing a 3.2% upside. In a report issued on February 7, BMO Capital also maintained a Hold rating on the stock with a $412 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
